A phase I trial of intravenous CG7870, a replication-selective, prostate-specific antigen-targeted oncolytic adenovirus, for the treatment of hormone-refractory, metastatic prostate cancer. (Q40479387)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	A phase I trial of intravenous CG7870, a replication-selective, prostate-specific antigen-targeted oncolytic adenovirus, for the treatment of hormone-refractory, metastatic prostate cancer.	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

A phase I trial of intravenous CG7870, a replication-selective, prostate-specific antigen-targeted oncolytic adenovirus, for the treatment of hormone-refractory, metastatic prostate cancer. (English)

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

phase I clinical trial

0 references

oncolytic virus

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

12

object named as

George Wilding

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

1

object named as

Eric J Small

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

author name string

Michael A Carducci

2

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

James M Burke

3

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

Ron Rodriguez

4

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

Lawrence Fong

5

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

Lynn van Ummersen

6

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

D C Yu

7

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

Junko Aimi

8

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

Dale Ando

9

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

Peter Working

10

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

David Kirn

11

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

language of work or name

1 reference

based on heuristic

inferred from title

publication date

9 May 2006

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

Molecular Therapy

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

14

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

1

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

107-117

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

Replication-selective virotherapy for cancer: Biological principles, risk management and future directions

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2006.02.011

7 January 2021

Replication-selective oncolytic adenoviruses: virotherapy aimed at genetic targets in cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2006.02.011

7 January 2021

ONYX-015, an E1B gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2006.02.011

7 January 2021

Clinical research results with dl1520 (Onyx-015), a replication-selective adenovirus for the treatment of cancer: what have we learned?

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2006.02.011

7 January 2021

a controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2006.02.011

7 January 2021

Intra-arterial administration of a replication-selective adenovirus (dl1520) in patients with colorectal carcinoma metastatic to the liver: a phase I trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2006.02.011

7 January 2021

Intravenous infusion of a replication-selective adenovirus (ONYX-015) in cancer patients: safety, feasibility and biological activity

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2006.02.011

7 January 2021

Phase II Trial of Intravenous CI-1042 in Patients With Metastatic Colorectal Cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2006.02.011

7 January 2021

Intravascular adenoviral agents in cancer patients: lessons from clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2006.02.011

7 January 2021

Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2006.02.011

7 January 2021

A novel three-pronged approach to kill cancer cells selectively: concomitant viral, double suicide gene, and radiotherapy

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2006.02.011

7 January 2021

Adenovirus-mediated p53 gene transfer in sequence with cisplatin to tumors of patients with non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2006.02.011

7 January 2021

TNFerade biologic, an adenovector with a radiation-inducible promoter, carrying the human tumor necrosis factor alpha gene: a phase I study in patients with solid tumors

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2006.02.011

7 January 2021

Prostate cancer update

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2006.02.011

7 January 2021

Molecular-genetic imaging: current and future perspectives

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2006.02.011

7 January 2021

Cytokines in adenoviral disease in children: association of interleukin-6, interleukin-8, and tumor necrosis factor alpha levels with clinical outcome

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2006.02.011

7 January 2021

Tumour necrosis factor in man: clinical and biological observations

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2006.02.011

7 January 2021

Fatal systemic inflammatory response syndrome in a ornithine transcarbamylase deficient patient following adenoviral gene transfer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2006.02.011

7 January 2021

A pilot study of in vivo liver-directed gene transfer with an adenoviral vector in partial ornithine transcarbamylase deficiency

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2006.02.011

7 January 2021

Replication-selective adenoviruses as oncolytic agents

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2006.02.011

7 January 2021

HCAR and MCAR: the human and mouse cellular receptors for subgroup C adenoviruses and group B coxsackieviruses

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2006.02.011

7 January 2021

Ablating CAR and integrin binding in adenovirus vectors reduces nontarget organ transduction and permits sustained bloodstream persistence following intraperitoneal administration

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2006.02.011

7 January 2021

Polymer-coated adenovirus permits efficient retargeting and evades neutralising antibodies.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2006.02.011

7 January 2021

Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2006.02.011

7 January 2021

Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2006.02.011

7 January 2021

An adenovirus E1A mutant that demonstrates potent and selective systemic anti-tumoral efficacy

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2006.02.011

7 January 2021

Pre-existent adenovirus antibody inhibits systemic toxicity and antitumor activity of CN706 in the nude mouse LNCaP xenograft model: implications and proposals for human therapy

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2006.02.011

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/J.YMTHE.2006.02.011

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q40479387&oldid=2186407224"